CA2768658C - Methods for generating radioimmunoconjugates - Google Patents

Methods for generating radioimmunoconjugates Download PDF

Info

Publication number
CA2768658C
CA2768658C CA2768658A CA2768658A CA2768658C CA 2768658 C CA2768658 C CA 2768658C CA 2768658 A CA2768658 A CA 2768658A CA 2768658 A CA2768658 A CA 2768658A CA 2768658 C CA2768658 C CA 2768658C
Authority
CA
Canada
Prior art keywords
acid
reaction mixture
dota
antibody
hum195
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2768658A
Other languages
English (en)
French (fr)
Other versions
CA2768658A1 (en
Inventor
Jaime Simon
A. Gaylord King
Josue Manuel Moreno Bermudez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of CA2768658A1 publication Critical patent/CA2768658A1/en
Application granted granted Critical
Publication of CA2768658C publication Critical patent/CA2768658C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2768658A 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates Active CA2768658C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
US61/227,710 2009-07-22
PCT/US2010/042885 WO2011011592A1 (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Publications (2)

Publication Number Publication Date
CA2768658A1 CA2768658A1 (en) 2011-01-27
CA2768658C true CA2768658C (en) 2018-04-03

Family

ID=43499411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768658A Active CA2768658C (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Country Status (8)

Country Link
US (1) US9603954B2 (cg-RX-API-DMAC7.html)
EP (1) EP2456472B1 (cg-RX-API-DMAC7.html)
JP (2) JP5985392B2 (cg-RX-API-DMAC7.html)
CN (2) CN102596258B (cg-RX-API-DMAC7.html)
CA (1) CA2768658C (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00551A (cg-RX-API-DMAC7.html)
RU (2) RU2704802C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011011592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
US11660357B2 (en) * 2014-05-16 2023-05-30 David A. Scheinberg One-step labeling of antibodies to high specific activity with actinium-225
EP4400507B1 (en) * 2015-09-08 2026-08-05 Waters Technologies Corporation Multidimensional chromatography method for analysis of antibody-drug conjugates
AU2017376822B2 (en) * 2016-12-16 2023-08-03 The Australian National University Radiolabelled material for targeted administration
CA3050094C (en) 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
EP3661557B1 (en) * 2017-07-31 2025-09-03 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
EP4210752A4 (en) * 2020-09-11 2025-09-24 Actinium Pharmaceuticals Inc Trophoblastic Glycoprotein Radiation Immunotherapy for the Treatment of Solid Cancers
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
US12668622B2 (en) 2022-03-24 2026-06-30 Actinium Pharmaceuticals, Inc. Calreticulin nanobodies
WO2023183927A2 (en) * 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
KR20240167790A (ko) 2022-03-30 2024-11-28 니혼 메디피직스 가부시키가이샤 복합체의 제조 방법
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
WO2025213061A2 (en) 2024-04-04 2025-10-09 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
TW202611088A (zh) 2024-07-23 2026-03-16 美商雅博得樂醫療公司 5t4結合多肽及其用途
CN121899313B (zh) * 2026-03-24 2026-07-03 云核医药(天津)有限公司 一种锕[225Ac]缀合物的放射化学纯度的检测方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
IL87405A0 (en) 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
ATE134999T1 (de) 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
CA2034484C (en) 1989-06-19 2000-08-15 Maurits W. Geerlings Radioimmunotherapy using .alpha.-particles emission
US5254328A (en) 1989-07-12 1993-10-19 Mallinckrodt Medical, Inc. Method of preparing a radiodiagnostic comprising a gaseous radionuclide, as well as a radionuclide generator suitable for using said method
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法
US7074405B1 (en) 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
CA2422291C (en) * 2000-09-15 2011-03-08 Sloan-Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
EP1383544A4 (en) * 2001-04-09 2007-12-12 Progenics Pharm Inc IMMUNOTOXINS ANTI-CD19
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) * 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗edbフィブロネクチンドメイン抗体l19−sip及び抗−egfr−抗体の組合せ

Also Published As

Publication number Publication date
WO2011011592A1 (en) 2011-01-27
JP5985392B2 (ja) 2016-09-06
IN2012DN00551A (cg-RX-API-DMAC7.html) 2015-06-12
RU2015137512A (ru) 2018-12-25
JP2013500258A (ja) 2013-01-07
EP2456472A1 (en) 2012-05-30
EP2456472B1 (en) 2024-03-27
CA2768658A1 (en) 2011-01-27
RU2015137512A3 (cg-RX-API-DMAC7.html) 2019-04-02
EP2456472A4 (en) 2014-08-27
CN102596258A (zh) 2012-07-18
RU2012106301A (ru) 2013-08-27
US20120220754A1 (en) 2012-08-30
RU2704802C2 (ru) 2019-10-31
CN104710504A (zh) 2015-06-17
CN102596258B (zh) 2015-01-28
JP2016199583A (ja) 2016-12-01
US9603954B2 (en) 2017-03-28
EP2456472C0 (en) 2024-03-27
HK1211304A1 (en) 2016-05-20
CN104710504B (zh) 2019-09-13
RU2565402C2 (ru) 2015-10-20

Similar Documents

Publication Publication Date Title
US9603954B2 (en) Methods for generating radioimmunoconjugates
JP2025143317A (ja) ポリペプチドの放射性標識
Di Bartolo et al. New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr
Sarrett et al. Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy
CA2786655C (en) Novel radioimmunoconjugates that binds human cd37
AU687204B2 (en) Thiolation of proteins for radionuclide-based radioimmunodetection and radioimmunotherapy
JP3095415B2 (ja) 免疫複合体の調製及び使用
CA2290987A1 (en) Radioprotectant for peptides labeled with radioisotope
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
Coliva et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas
Yoo et al. N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein
US20150157742A1 (en) SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
N’Guessan et al. Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering
HK1211304B (en) Methods for generating radioimmunoconjugates
Hinkle et al. Indium-111-monoclonal antibodies in radioimmunoscintigraphy
CA2836313A1 (en) Synthesis of biological compounds labeled with the alpha emitter ac-225
Bensimon et al. Antibody radiolabeling
HK1195736B (en) Radioimmunoconjugates and their use
HK1179157B (en) Radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150721

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240725

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260709

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260709